Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

A Short-Order Oncology Start-Up: Non-Profit Tackles Drug Shortages

This article was originally published in RPM Report

  • Analysis

Executive Summary

Drug shortages are a big problem in cancer, where many generic sterile injectables are both life-saving and irreplaceable. Some oncologists have decided to take control and form a manufacturer of their own.

You may also be interested in...



Who Will Solve The Shortage Problem? Hospital Non-Profit Is Latest Idea

Non-profit probably won’t ever be significant threat to industry – but frustration with chronic shortages could prompt policy changes that are.

Early Notification Legislation: What The Bills Say

Both houses have introduced legislation to require manufacturers to notify FDA in advance of planned interruptions or as soon as possible when facing a shortage. Here’s a look at the details.

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

Table

View full table

Tags:
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS080875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By